Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases
Authors:
- 25 May 2021
- journal article
- review article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 18 (1) , 152-158
Abstract
The exact signaling leading to neurological dysfunction in neurodegenerative diseases is currently unknown. We hypothesize that the c‐Jun N‐terminal kinase (JNK) signaling pathway is a potential therapeutic target for neurodegenerative diseases. This postulate rests on extensive data from cell and animal experimental studies, demonstrating that JNK signaling plays a crucial role in the pathogenesis of neurodegenerative diseases. The sustained activation of JNK leads to synaptic dysfunction and even neuronal apoptosis, ultimately resulting in memory deficits and neurodegeneration. JNK phosphorylates the amyloid precursor protein and tau, ultimately resulting in the formation of extraneuronal senile plaques and intraneuronal neurofibrillary tangles. Our hypothesis could be validated by investigating the cerebral cortex of elderly chimpanzees injected with phosphorylated JNK or transgenic pig and chimpanzee models established using gene editing technology including CRISPR. This hypothesis provides clues for further understanding the molecular mechanisms of neurodegenerative diseases and the development of potential target therapeutic drugs.Keywords
Funding Information
- National Natural Science Foundation of China (31972741, 32072925, 31572576)
This publication has 46 references indexed in Scilit:
- c-Jun N-terminal Kinase Regulates Soluble Aβ Oligomers and Cognitive Impairment in AD Mouse ModelJournal of Biological Chemistry, 2011
- c-Jun N-terminal kinases in memory and synaptic plasticityReviews in the Neurosciences, 2011
- Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implicationsTrends in Neurosciences, 2010
- Pathological roles of MAPK signaling pathways in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- The JNK pathway amplifies and drives subcellular changes in tau phosphorylationNeuropharmacology, 2009
- JNK regulates APP cleavage and degradation in a model of Alzheimer's diseaseNeurobiology of Disease, 2009
- JNK pathway: diseases and therapeutic potentialActa Pharmacologica Sinica, 2007
- The JNK signal transduction pathwayCurrent Opinion in Cell Biology, 2007
- Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brainsNeuroscience Letters, 2006
- Targeting JNK3 for the treatment of neurodegenerative disordersDrug Discovery Today, 2004